United Therapeutics (UTHR) Cash & Equivalents (2009 - 2026)

United Therapeutics has disclosed Cash & Equivalents across 18 years of filings, most recently posting $1.3 billion for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.3 billion, down 32.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 32.64% YoY), and the FY2025 annual result was $1.6 billion, down 8.25% from the prior year.
• Cash & Equivalents came in at $1.3 billion for Q1 2026 at United Therapeutics, down from $1.6 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.9 billion in Q1 2025 to a low of $795.2 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $1.3 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Cash & Equivalents soared 51.81% in 2025 and slumped 32.64% in 2026, its largest moves.
• United Therapeutics' Cash & Equivalents stood at $961.2 million in 2022, then climbed by 25.65% to $1.2 billion in 2023, then soared by 40.53% to $1.7 billion in 2024, then dropped by 8.25% to $1.6 billion in 2025, then slipped by 17.82% to $1.3 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.3 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.